Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
gynäkologie + geburtshilfe
Erschienen in:

07.12.2018 | Mammakarzinom | Zertifizierte Fortbildung

Update der S3-Leitlinie

Aktuelle Therapiestrategien beim primären Mammakarzinom

verfasst von: Dr. med. Jasmin Festl, Prof. Dr. med. Achim Wöckel

Erschienen in: gynäkologie + geburtshilfe | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

In der aktualisierten S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms von Dezember 2017 haben sich auch Neuerungen für die Behandlung des frühen Brustkrebs’ ergeben. So hat sich vor allem im Hinblick auf das operative Vorgehen die Radikalität verringert. Die erweiterten Möglichkeiten der Bestrahlung und systemischen Therapie in der adjuvanten Situation sind ebenfalls in die neuen Empfehlungen eingegangen.
Literatur
1.
Robert-Koch-Institut. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Krebs in Deutschland für 2013/2014. 2017. 11. Ausg. Berlin; 2017
2.
3.
Buchholz TA et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014;32:1502–6CrossRefPubMed
4.
Voogd AC et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19:1688–97CrossRefPubMed
5.
Fisher B, Anderson S. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg. 1994;18:63–9CrossRefPubMed
6.
De La Cruz L et al. Overall Survival, Disease-Free Survival, Local Recurrence, and Nipple-Areolar Recurrence in the Setting of Nipple-Sparing Mastectomy: A Meta-Analysis and Systematic Review. Ann Surg Oncol. 2015;22:3241–9CrossRefPubMed
7.
Piper M et al. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg. 2013;70:435–7CrossRefPubMed
8.
9.
Hoffmann J, Wallwiener D. Classifying breast cancer surgery: a novel, complexity-based system for oncological, oncoplastic and reconstructive procedures, and proof of principle by analysis of 1225 operations in 1166 patients. BMC Cancer. 2009;9:108CrossRefPubMedPubMedCentral
10.
Andersson Y. et al. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg. 2012;99:226–31CrossRefPubMed
11.
Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75CrossRefPubMedPubMedCentral
12.
Giuliano AE et al. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264:413–20CrossRefPubMed
13.
Classe JM et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27:726–32CrossRefPubMed
14.
Boughey JC et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61CrossRefPubMedPubMedCentral
15.
Kuehn T et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18CrossRefPubMed
16.
Trentin C et al. Predictors of invasive breast cancer and lymph node involvement in ductal carcinoma in situ initially diagnosed by vacuum-assisted breast biopsy: experience of 733 cases. Breast. 2012;21:635–40CrossRefPubMed
17.
Chin-Lenn L et al. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy. Ann Surg Oncol. 2014;21:66–73CrossRefPubMed
18.
Virnig BA et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170–8CrossRefPubMed
19.
Narod SA et al. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol. 2015;1:888–96CrossRefPubMed
20.
Shamliyan T et al. Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010:121–9CrossRefPubMedPubMedCentral
21.
Marinovich ML et al. The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis. Ann Surg Oncol. 2016;23:3811–21CrossRefPubMedPubMedCentral
22.
Rudloff U et al. The influence of margin width and volume of disease near margin on benefit of radiation therapy for women with DCIS treated with breast-conserving therapy. Ann Surg. 2010;251:583–91CrossRefPubMed
23.
Lyman GH et al. Sentinel lymph node biopsy for patients with earlystage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365–83CrossRefPubMed
24.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16CrossRefPubMedCentral
25.
Haviland JS et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–94CrossRefPubMed
26.
Whelan TJ et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513–20CrossRefPubMed
27.
Bartelink H et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47–56CrossRefPubMed
28.
Warnberg F et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol. 2014;32:3613–8CrossRefPubMed
29.
Goodwin A et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. 2013;11:CD000563
30.
Goldhirsch A et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2011;22:1736–47CrossRefPubMedPubMedCentral
31.
32.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717CrossRef
33.
Sparano JA et al. Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. J Clin Oncol. 2015;33:2353–60CrossRefPubMedPubMedCentral
34.
Bria E et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer. 2006;106:2337–44CrossRefPubMed
35.
Martin M et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst. 2008;100:805–14CrossRefPubMed
36.
Moebus V et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010;28:2874–80CrossRefPubMed
37.
Jones S et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177–83CrossRefPubMed
38.
von Minckwitz G et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125:145–56CrossRefPubMed
39.
Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72CrossRefPubMed
40.
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84CrossRefPubMed
41.
Moja L et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243
42.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84CrossRefPubMedCentral
43.
Colleoni M et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:127–38CrossRefPubMed
44.
Davies C et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor- positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16CrossRefPubMedPubMedCentral
45.
Burstein HJ et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32:2255–69CrossRefPubMedPubMedCentral
46.
47.
Blok EJ et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst. 2018;110(1).CrossRef
Metadaten
Titel
Update der S3-Leitlinie
Aktuelle Therapiestrategien beim primären Mammakarzinom
verfasst von
Dr. med. Jasmin Festl
Prof. Dr. med. Achim Wöckel
Publikationsdatum
07.12.2018
Verlag
Springer Medizin
Erschienen in
gynäkologie + geburtshilfe / Ausgabe 6/2018
Print ISSN: 1439-3557
Elektronische ISSN: 2196-6435
DOI
https://doi.org/10.1007/s15013-018-1311-7

Weitere Artikel der Ausgabe 6/2018

Neue infektiöse Agenzien im Visier der Krebsforscher

Maternale Adipositas schadet Mutter und Kind

Chancen der Niederlassung nutzen! GenoGyn-Seminar am 23. März 2019

  • Verbandsmitteilung

Frauenheilkunde: wissenschaftlich fundiert und qualitativ hochwertig

Die besten Innovationen 2018

Inkontinenz: Wie aussagekräftig sind Einlagenanzahl und -gewicht?

Bildnachweise